Medicine and Dentistry
Patient
100%
Rheumatoid Arthritis
53%
Inpatient
32%
Psoriatic Arthritis
28%
Systemic Lupus Erythematosus
26%
Disease Activity
21%
Biological Product
21%
Therapeutic Procedure
18%
Spondylarthritis
15%
Hyperpnea
14%
Biosimilar
13%
COVID-19
12%
Disease Modifying Antirheumatic Drug
11%
Rheumatic Disease
10%
Hazard Ratio
10%
Vagus Nerve Stimulation
10%
Incidence
9%
Cohort Analysis
8%
Omega-3 Fatty Acid
8%
Smoking
7%
Computed Tomography
7%
Spontaneous Remission
7%
Association
7%
Chemotherapeutic Agent
7%
Drug
7%
Biological Marker
7%
Chest Physiotherapy
7%
Observational Study
6%
Polymyalgia Rheumatica
6%
Fatigue Impact Scale
6%
Etanercept
6%
Odds Ratio
6%
Fatigue
6%
Pain
6%
Tissues
5%
Mortality
5%
Adalimumab
5%
Psoriasis
5%
Follow up
5%
Nursing and Health Professions
Rheumatoid Arthritis
34%
Inpatient
29%
Patient
27%
Systemic Lupus Erythematosus
26%
Biological Product
19%
Heart Rate Variability
19%
Disease Activity
16%
Confidence Interval
16%
Hyperpnea
14%
Disease Modifying Antirheumatic Drug
11%
Vagus Nerve Stimulation
10%
Pain Intensity
9%
Pain
9%
Spondylarthritis
8%
Psoriatic Arthritis
8%
Patient-Reported Outcome
7%
Rheumatic Disease
7%
Incidence
7%
Odds Ratio
6%
Fatigue
6%
Parameters
5%
Mortality
5%
Vagus Tone
5%
Control
5%
Dose
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
36%
Psoriatic Arthritis
26%
Disease Activity
18%
Systemic Lupus Erythematosus
15%
Biological Product
13%
Biosimilar Agent
13%
Incidence
9%
Omega-3 Fatty Acid
9%
Spondylarthritis
8%
Biological Marker
8%
Hyperpnea
6%
Case-Control Study
6%
Rheumatic Polymyalgia
6%
Disease Modifying Antirheumatic Drug
6%
Remission
6%
Rheumatic Disease
5%
Mortality
5%
Adalimumab
5%
Etanercept
5%